Division of Allergy and Immunology, Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA; Beth Israel Deaconess Center, Cardiovascular institute, 330 Brookline Avenue, Boston, MA 02215, USA.
Division of Respiratory Diseases, Boston Children's Hospital, Boston, MA, USA.
Clin Chest Med. 2019 Mar;40(1):163-177. doi: 10.1016/j.ccm.2018.10.010.
Corticosteroids are the most effective treatment for asthma; inhaled corticosteroids (ICSs) are the first-line treatment for children and adults with persistent symptoms. ICSs are associated with significant improvements in lung function. The anti-inflammatory effects of corticosteroids are mediated by both genomic and nongenomic factors. Variation in the response to corticosteroids has been observed. Patient characteristics, biomarkers, and genetic features may be used to predict response to ICSs. The existence of multiple mechanisms underlying glucocorticoid insensitivity raises the possibility that this might indeed reflect different diseases with a common phenotype.
皮质类固醇是治疗哮喘最有效的药物;吸入皮质类固醇(ICSs)是持续性症状儿童和成人的一线治疗药物。ICSs 可显著改善肺功能。皮质类固醇的抗炎作用通过基因组和非基因组因素介导。已经观察到对皮质类固醇的反应存在差异。患者特征、生物标志物和遗传特征可用于预测 ICSs 的反应。糖皮质激素不敏感的多种机制的存在提出了这样一种可能性,即这确实可能反映了具有共同表型的不同疾病。